Bryan D Bryson
Overview
Explore the profile of Bryan D Bryson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCaffrey E, Delmastro A, Fitzhugh I, Ranek J, Douglas S, Peters J, et al.
bioRxiv
. 2025 Mar;
PMID: 40027668
Despite being heavily infiltrated by immune cells, tuberculosis (TB) granulomas often subvert the host response to (Mtb) infection and support bacterial persistence. We previously discovered that human TB granulomas are...
2.
Peters J, Irvine E, Makatsa M, Rosenberg J, Wadsworth 2nd M, Hughes T, et al.
Sci Adv
. 2025 Jan;
11(1):eadq8229.
PMID: 39742484
Intradermal Bacillus Calmette-Guérin (BCG) is the most widely administered vaccine, but it does not sufficiently protect adults against pulmonary tuberculosis. Recent studies in nonhuman primates show that intravenous BCG administration...
3.
Lepe B, Zheng C, Leddy O, Allsup B, Solomon S, Bryson B
Microbiol Spectr
. 2024 Dec;
13(2):e0227724.
PMID: 39688428
Tuberculosis (TB) is the leading cause of infectious disease death and lacks a vaccine capable of protecting adults from pulmonary TB. The bacterial surface is a critical interface that shapes...
4.
Leddy O, Cui Y, Ahn R, Stopfer L, Choe E, Kim D, et al.
Nat Protoc
. 2024 Oct;
PMID: 39438697
Vaccines and immunotherapies that target peptide-major histocompatibility complexes (peptide-MHCs) have the potential to address multiple unmet medical needs in cancer and infectious disease. Designing vaccines and immunotherapies to target peptide-MHCs...
5.
Grace P, Peters J, Sixsmith J, Lu R, Luedeman C, Fenderson B, et al.
bioRxiv
. 2024 Oct;
PMID: 39416184
the causative agent of tuberculosis (TB), is a leading cause of death by an infectious disease globally, with no efficacious vaccine. Antibodies are implicated in control, but the mechanisms of...
6.
Leddy O, Yuki Y, Carrington M, Bryson B, White F
bioRxiv
. 2024 Sep;
PMID: 39314426
Vaccine-elicited T cell responses can contribute to immune protection against emerging infectious disease risks such as antimicrobials-resistant (AMR) microbial pathogens and viruses with pandemic potential, but rapidly identifying appropriate targets...
7.
Allsup B, Gharpure S, Bryson B
bioRxiv
. 2024 Sep;
PMID: 39282337
Proteomic analyses of the phagosome has significantly improved our understanding of the proteins which contribute to critical phagosome functions such as apoptotic cell clearance and microbial killing. However, previous methods...
8.
Irvine E, Nikolov A, Khan M, Peters J, Lu R, Sixsmith J, et al.
Nat Microbiol
. 2024 Aug;
9(9):2369-2382.
PMID: 39174703
Mounting evidence indicates that antibodies can contribute towards control of tuberculosis (TB). However, the underlying mechanisms of humoral immune protection and whether antibodies can be exploited in therapeutic strategies to...
9.
Lepe B, Zheng C, Leddy O, Allsup B, Solomon S, Bryson B
bioRxiv
. 2024 Jul;
PMID: 39005324
Tuberculosis (TB), caused by (Mtb), is the leading cause of infectious disease death and lacks a vaccine capable of protecting adults from pulmonary TB. Studies have shown that Mtb uses...
10.
Hendrix S, Mreyoud Y, McNehlan M, Smirnov A, Chavez S, Hie B, et al.
J Immunol
. 2024 Apr;
212(11):1766-1781.
PMID: 38683120
Better understanding of the host responses to Mycobacterium tuberculosis infections is required to prevent tuberculosis and develop new therapeutic interventions. The host transcription factor BHLHE40 is essential for controlling M....